<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02568254</url>
  </required_header>
  <id_info>
    <org_study_id>CR-5735</org_study_id>
    <nct_id>NCT02568254</nct_id>
  </id_info>
  <brief_title>Evaluation of Three Daily Disposable Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site, 8-visit, double-masked, cross-over study involving three marketed
      products as study lenses. Participants will be randomly assigned each lens type, which will
      be worn for approximately two weeks (12 +/- 2 days) each. Participants will undergo a minimum
      washout period of 3 days before entering the study and undergo a minimum 7 day washout period
      between dispensing each lens type.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2015</start_date>
  <completion_date type="Actual">January 18, 2016</completion_date>
  <primary_completion_date type="Actual">January 18, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Comfort</measure>
    <time_frame>2- Week Follow-up</time_frame>
    <description>Clue comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Visual Acuity</condition>
  <arm_group>
    <arm_group_label>Lens 1/ Lens 2/ Lens 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens 1 / Lens 3 / Lens 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens 2/ Lens 3/ Lens 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens 2 / Lens 1/ Lens 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens 3 / Lens 1 / Lens 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens 3 / Lens 2 / Lens 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens 1 (etafilcon A)</intervention_name>
    <description>Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).</description>
    <arm_group_label>Lens 1/ Lens 2/ Lens 3</arm_group_label>
    <arm_group_label>Lens 1 / Lens 3 / Lens 2</arm_group_label>
    <arm_group_label>Lens 2/ Lens 3/ Lens 1</arm_group_label>
    <arm_group_label>Lens 2 / Lens 1/ Lens 3</arm_group_label>
    <arm_group_label>Lens 3 / Lens 1 / Lens 2</arm_group_label>
    <arm_group_label>Lens 3 / Lens 2 / Lens 1</arm_group_label>
    <other_name>1-Day Acuvue® Moist®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens 2 (nelfilcon A)</intervention_name>
    <description>Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).</description>
    <arm_group_label>Lens 1/ Lens 2/ Lens 3</arm_group_label>
    <arm_group_label>Lens 1 / Lens 3 / Lens 2</arm_group_label>
    <arm_group_label>Lens 2/ Lens 3/ Lens 1</arm_group_label>
    <arm_group_label>Lens 2 / Lens 1/ Lens 3</arm_group_label>
    <arm_group_label>Lens 3 / Lens 1 / Lens 2</arm_group_label>
    <arm_group_label>Lens 3 / Lens 2 / Lens 1</arm_group_label>
    <other_name>Dailies® AquaComfort Plus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens 3 (nesofilcon A)</intervention_name>
    <description>Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).</description>
    <arm_group_label>Lens 1/ Lens 2/ Lens 3</arm_group_label>
    <arm_group_label>Lens 1 / Lens 3 / Lens 2</arm_group_label>
    <arm_group_label>Lens 2/ Lens 3/ Lens 1</arm_group_label>
    <arm_group_label>Lens 2 / Lens 1/ Lens 3</arm_group_label>
    <arm_group_label>Lens 3 / Lens 1 / Lens 2</arm_group_label>
    <arm_group_label>Lens 3 / Lens 2 / Lens 1</arm_group_label>
    <other_name>Biotrue ONEday</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
             receive a fully executed copy of the form;

          -  The subject must appear able and willing to adhere to the instructions set forth in
             this clinical protocol;

          -  The subject must be willing and able to follow instructions and maintain the
             appointment schedule;

          -  The subject must be between the age of 18 and 40 years (inclusive);

          -  The subject's vertex corrected spherical equivalent distance refraction must be in the
             range of -0.50 Diopters (D) to -6.00 D in each eye (inclusive);

          -  The subject's refractive cylinder must not exceed -1.25 Diopters of Cylinder (DC) in
             each eye after vertexing to the corneal plane;

          -  The subject must have best corrected visual acuity of 0.2 Logarithm of the Minimum
             Angle of Resolution (logMAR) or better in each eye;

          -  The subject must be a current wearer of spherical, soft contact lenses (no toric,
             bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5
             days/week and at least 8 hours/day during the month prior to enrollment;

          -  The subject must own a wearable pair of spectacles and wear them the day of the
             initial visit;

          -  The subject must be an existing wearer of spherical, soft contact lenses in both eyes;

          -  The subject must have normal eyes (i.e., no ocular medications or infections of any
             type);

          -  The subject must be willing to wear the study lenses for a minimum eight hours per
             day.

        Exclusion Criteria:

          -  Any ocular or systemic allergies or diseases that may interfere with contact lens wear
             (at the investigator's discretion);

          -  Any systemic disease, autoimmune disease, or use of medication, which may interfere
             with contact lens wear (at the investigator's discretion);

          -  Currently pregnant or lactating (subjects who become pregnant during the study will be
             discontinued);

          -  Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious
             immunosuppressive disease;

          -  Any active ocular infection;

          -  Is using any topical medications (excluding artificial tears (ATS)) up to two weeks
             prior to the screening visit;

          -  Any participants whose habitual contact lenses are used as an extended wear regimen;

          -  Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of
             recurrent corneal erosions, aphakia, or moderate or above corneal distortion by
             keratometry;

          -  Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy,
             photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK),
             etc.);

          -  Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal
             staining, or any other abnormalities of the cornea which would contraindicate contact
             lens wear; or clinically significant (grade 3 or 4) tarsal abnormalities or bulbar
             injection which might interfere with contact lens wear;

          -  Any known hypersensitivity or allergic reaction to the study products;

          -  Participation in any contact lens or lens care product clinical trial within 7 days
             prior to study enrollment;

          -  Employee or family member of the Centre for Contact Lens Research (e.g., Investigator,
             Coordinator, Technician).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Contact Lens Research</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <results_first_submitted>June 12, 2017</results_first_submitted>
  <results_first_submitted_qc>July 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2017</results_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 78 subjects were enrolled in this study. Of the enrolled subjects 74 subjects were dispensed at least 1 study lens and 4 subjects did not meet the eligbility criteria. Of the dispensed subjects 72 completed the study and 2 subjects were discontinued.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A/ Nelfilcon A/ Nesofilcon A</title>
          <description>All subjects that were randomized to receive the etafilcon A lens first, the nelfilcon A lens second and the nesofilcon A lens third.</description>
        </group>
        <group group_id="P2">
          <title>Etafilcon A/ Nesofilcon A/ Nelfilcon A</title>
          <description>All subjects that were randomized to receive the etafilcon A lens first, the nesofilcon A lens second and the nelfilcon A lens third.</description>
        </group>
        <group group_id="P3">
          <title>Nelfilcon A/ Nesofilcon A/ Etafilcon A</title>
          <description>All subjects that were randomized to receive the nelfilcon A lens first, the nesofilcon A lens second and the etafilcon A lens third.</description>
        </group>
        <group group_id="P4">
          <title>Nelfilcon A/ Etafilcon A/ Nesofilcon A</title>
          <description>All subjects that were randomzied to receive the nelfilcon A lens first, the etafilcon A lens second and the nesofilcon A lens third.</description>
        </group>
        <group group_id="P5">
          <title>Nesolfilcon A/ Etafilcon A/ Nelfilcon A</title>
          <description>All subjects that were randomized to receive the nesofilcon A lens first, the etafilcon A lens second and the nelfilcon A lens third.</description>
        </group>
        <group group_id="P6">
          <title>Nesofilcon A/ Nelfilcon A/Etafilcon A</title>
          <description>All subjects that were randomized to receive the nesofilcon A lens first, the nelfilcon A lens second and the etafilcon A lens third.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unstatisfactory Lens fitting</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were dispensed at least 1 study lens.</population>
      <group_list>
        <group group_id="B1">
          <title>Dispensed Subjects</title>
          <description>All subjects that were dispensed at least 1 study lens.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Comfort</title>
        <description>Clue comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
        <time_frame>2- Week Follow-up</time_frame>
        <population>Subjects that completed all study visits without a major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
            <description>All subjects that wore the etafilcon A lens during any one of the 3 periods in the study.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A</title>
            <description>All subjects that wore the nelfilcon A lens in any of the 3 periods of the study.</description>
          </group>
          <group group_id="O3">
            <title>Nesofilcon A</title>
            <description>All subjects that wore the nesofilcon A lens in any of the 3 periods in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Comfort</title>
          <description>Clue comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.</description>
          <population>Subjects that completed all study visits without a major protocol deviation.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.74" spread="25.350"/>
                    <measurement group_id="O2" value="48.14" spread="25.166"/>
                    <measurement group_id="O3" value="57.32" spread="25.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire duration of the study. Approximately 6 weeks per subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A</title>
          <description>All subjects that wore the etafilcon A lens during any one of the 3 periods in the study.</description>
        </group>
        <group group_id="E2">
          <title>Nelfilcon A</title>
          <description>All subjects that wore the nelfilcon A lens in any of the 3 periods of the study.</description>
        </group>
        <group group_id="E3">
          <title>Nesofilcon A</title>
          <description>All subjects that wore the nesofilcon A lens in any of the 3 periods in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Caution of interpretation of results: A significant first-order carryover effect was noted in the study analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chantal Coles-Brennan BSc, OD, FAAOPrincipal Research Optometrist</name_or_title>
      <organization>Johnson &amp; Johnson Vision Care Inc.</organization>
      <phone>904 443 3449</phone>
      <email>CColesb@ITS.JNJ.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

